Stockscreener 앱 받기
35.07
2.47%
-0.89
전일 마감가:
$35.96
열려 있는:
$35.79
하루 거래량:
639.26K
Relative Volume:
1.57
시가총액:
$2.45B
수익:
-
순이익/손실:
$-195.21M
주가수익비율:
-11.04
EPS:
-3.1763
순현금흐름:
$-176.19M
1주 성능:
+3.57%
1개월 성능:
+11.30%
6개월 성능:
+35.46%
1년 성능:
+76.85%
1일 변동 폭
$33.97
$36.25
1주일 범위
$33.00
$36.60
52주 변동 폭
$19.12
$36.60
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
35.07 | 2.45B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-09 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics
FDA accepts Pharvaris NDA for oral HAE attack treatment drug - Investing.com
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
Pharvaris (PHVS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
PHVSPharvaris NV Latest SEC Filings - Finviz
Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com
Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan
Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan
PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan
PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan
Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan
Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan
PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan
PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan
8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan
Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView
Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily
PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et
Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS) - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Price to sales forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to book forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Enterprise value to EBITDA forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to earnings forward of Pharvaris N.V. – LS:A2QNWS - TradingView
[144] Pharvaris N.V. SEC Filing - Stock Titan
Enterprise value to EBIT forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM - TipRanks
[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan
PHVS Forecast — Price Target — Prediction for 2027 - TradingView
Pharvaris N.V. Actuals & Estimates (FWB:9EN) - TradingView
Form 144 Pharvaris N.V. For: 25 June By Investing.com - Investing.com India
9EN Forecast — Price Target — Prediction for 2027 - TradingView
PHVS (NASDAQ) director 10b5-1 sales include 29,070 shares on 04/30/2026 - Stock Titan
PHVS (NASDAQ: PHVS) insider plans to sell 15,000 shares after option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $46. - GuruFocus
PHVS (NASDAQ) reports director/entity 10b5-1 sales on April 22–30, 2026 - Stock Titan
PHVS (NASDAQ) files Form 144: 2,300 shares tied to option exercise - Stock Titan
Pharvaris (PHVS) CMO sells 300 shares in scheduled 10b5-1 trade - Stock Titan
Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction - Sahm
PHVS Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Clinical ProgressRevenue Miss Report - dars.gov.et
PHVS reports 10b5-1 sales and option exercise (PHVS) - Stock Titan
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):